Western Asset Variable Rate Str (GFY) Is At $16.91 Formed Wedge; Ranger Investment Management LP Lowered By $17.25 Million Its Supernus Pharmaceuticals (SUPN) Holding

Western Asset Variable Rate Str (GFY) formed wedge down with $15.90 target or 6.00% below today’s $16.91 share price. Western Asset Variable Rate Str (GFY) has $78.94 million valuation. It closed at $16.91 lastly. It is down 0.53% since April 17, 2017 and is downtrending. It has underperformed by 12.08% the S&P500.

Ranger Investment Management Lp decreased Supernus Pharmaceuticals Inc. (SUPN) stake by 44.74% reported in 2017Q4 SEC filing. Ranger Investment Management Lp sold 442,371 shares as Supernus Pharmaceuticals Inc. (SUPN)’s stock rose 16.22%. The Ranger Investment Management Lp holds 546,469 shares with $21.78 million value, down from 988,840 last quarter. Supernus Pharmaceuticals Inc. now has $2.33 billion valuation. The stock decreased 0.11% or $0.05 during the last trading session, reaching $45.25. About 76,534 shares traded. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has risen 46.59% since April 17, 2017 and is uptrending. It has outperformed by 35.04% the S&P500.

Among 11 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Supernus Pharmaceuticals had 38 analyst reports since August 26, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, October 23 by Cowen & Co. The company was maintained on Monday, July 17 by Stifel Nicolaus. The firm earned “Buy” rating on Thursday, August 4 by Jefferies. The firm has “Outperform” rating given on Thursday, November 5 by Northland Capital. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has “Buy” rating given on Wednesday, November 8 by Stifel Nicolaus. The stock has “Buy” rating by FBR Capital on Wednesday, October 18. The rating was maintained by Cantor Fitzgerald with “Buy” on Monday, November 6. The rating was upgraded by Janney Capital on Monday, December 4 to “Buy”. The firm has “Neutral” rating by PiperJaffray given on Monday, July 17. On Wednesday, February 28 the stock rating was maintained by Piper Jaffray with “Hold”.

Since January 2, 2018, it had 0 insider purchases, and 8 insider sales for $10.98 million activity. Bhatt Padmanabh P. also sold $960,716 worth of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on Monday, January 22. On Friday, January 12 Vaughn Victor sold $258,928 worth of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) or 5,750 shares. 50,000 shares were sold by PATRICK GREGORY S, worth $2.18M.

Analysts await Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to report earnings on May, 8. They expect $0.33 earnings per share, up 73.68% or $0.14 from last year’s $0.19 per share. SUPN’s profit will be $17.01 million for 34.28 P/E if the $0.33 EPS becomes a reality. After $0.44 actual earnings per share reported by Supernus Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -25.00% negative EPS growth.

Investors sentiment increased to 1.1 in Q4 2017. Its up 0.12, from 0.98 in 2017Q3. It improved, as 22 investors sold SUPN shares while 93 reduced holdings. 43 funds opened positions while 83 raised stakes. 47.19 million shares or 3.19% less from 48.75 million shares in 2017Q3 were reported. 755,422 were accumulated by Wells Fargo And Mn. Intrust Commercial Bank Na, a Kansas-based fund reported 6,953 shares. D E Shaw holds 0% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 12,457 shares. Serv Automobile Association holds 86,672 shares. Arizona State Retirement Systems holds 0.03% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 86,161 shares. Metropolitan Life Insur has 15,717 shares. Moreover, Scout has 0.59% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Tiaa Cref Inv Limited Liability reported 0% stake. Numeric Investors Ltd Limited Liability Company holds 49,765 shares or 0.01% of its portfolio. Millennium Limited Liability Company has 531,397 shares for 0.03% of their portfolio. Blackrock reported 6.90 million shares. Bancshares Of Montreal Can invested 0% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Rothschild Asset Management Inc stated it has 0.46% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Neumeier Poma Invest Counsel Limited Liability reported 522,495 shares. Sei Invests invested in 0.03% or 228,556 shares.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Institutional Positions Chart